ImmunityBio Faces Class Action Lawsuit Amid FDA's Warning of Misleading Cancer Treatment Claims

ImmunityBio's Legal Troubles: A Deep Dive into the Recent Securities Class Action

In recent news, ImmunityBio, Inc. (NASDAQ: IBRX) is facing serious legal challenges as a securities class action lawsuit has been filed against the company. This case seeks to represent investors who purchased or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026. The lawsuit comes in the wake of alarming claims made by the U.S. Food and Drug Administration (FDA) about misleading statements regarding the company's lead product, Anktiva.

Background on ImmunityBio

ImmunityBio is a biotechnology firm specializing in the development and commercialization of innovative immunotherapies aimed at enhancing the body’s immune response to combat cancer and infectious diseases. Their flagship product, Anktiva, is an FDA-approved immunotherapy used in conjunction with Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC).

The Lawsuit

On March 24, 2026, the FDA issued a warning letter to ImmunityBio, indicating that certain claims made by Dr. Patrick Soon-Shiong, the company’s executive chairman and Chief Scientific and Medical Officer, were misleading. During a podcast titled "Is the FDA BLOCKING Life Saving Cancer Treatments?", Dr. Soon-Shiong stated that while Anktiva is approved for bladder cancer, it has the potential to treat all types of cancer. This has raised significant concerns about the accuracy of these claims and the possible implications for patients.

The FDA's letter pointed out that promotional materials—including the podcast and a TV advertisement—created the false impression that Anktiva could cure or prevent all cancers. Furthermore, the FDA emphasized that there was no supporting data for such extraordinary effectiveness claims. As a result, this damaging news led to a staggering drop of over 21% in ImmunityBio’s stock on the same day, which erased nearly $2 billion from the company's market capitalization.

Hagens Berman, a law firm specializing in investor rights, has initiated this class action investigation into the matter, urging affected shareholders to step forward. They are also seeking any witnesses who may provide information relevant to the claims against the company.

Regulatory Implications

The FDA's engagement highlights the significant regulatory scrutiny biotechnology companies face concerning marketing claims. The implications of making misleading statements can not only result in substantial financial loss for investors but can also pose a potential risk to patients who may misinterpret the efficacy of their treatment options.

Conclusion

As the legal battle unfolds, investors are being advised to stay informed about the developments in this case. The ongoing investigation dives deeper into the actions and decisions made by ImmunityBio’s leadership and their impact on shareholders. For those who have experienced substantial losses due to these events, it is crucial to consider potential legal recourse. The outcome of this lawsuit could set a significant precedent regarding accountability and transparency in the biotechnology sector going forward.